McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
A $5.8 billion deal to take Option Care private signals a major consolidation push in health‑care infusion services.
Evidence dossier
Intelligence passport
Measured timeline
-
Detected
-
Latest coverage observed
-
Peak measured velocity
-
Evidence threshold reached
-
Outcome review added
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
- Velocity & Diffusion: Coverage exploded across 4 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: A $5.8 billion deal to take Option Care private signals a major consolidation push in health‑care infusion services.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
A $5.8 billion acquisition was announced for infusion‑therapy provider Option Care, pricing the deal at $32.05 per share. The transaction pairs pharmacy giant McKesson with private‑equity firm Clayton, Dubilier & Rice (CD&R) as co‑buyers.
The coverage places the transaction among the largest health‑care buyouts this year, alongside Energy Transfer’s $2.6 billion purchase of Vaquero, highlighting a wave of multi‑billion deals in the sector. Regulatory approval and financing steps are expected to follow.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. Updated 44d ago.
Who reported it (5)
-
McKesson part of $5.8 billion buyout; Energy Transfer to buy Vaquero for $2.6 billionThe Business Journals · 46d ago
-
Option Care Health Agrees to $5.8 Billion Acquisition by CD&R and McKesson at $32.05 Per ShareYahoo Finance · 46d ago
-
McKesson, CD&R to Buy Option Care in $5.8 Billion DealBloomberg.com · 46d ago
-
-
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reportsReuters · 46d ago
The obvious questions
What is the purchase price and per‑share amount for Option Care?
The acquisition values Option Care at $5.8 billion, or $32.05 per share.
Who are the acquiring parties in the transaction?
Pharmacy distributor McKesson and private‑equity firm Clayton, Dubilier & Rice (CD&R) are the co‑buyers.
What is the current status of the deal?
Reuters reports the deal is described as near $5 billion‑plus and moving toward finalisation, based on an FT report.
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
Hackers claim to have stolen 284 million patient records from McKesson, a company that supplies one in three hospital prescriptions.
McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets
McKesson is spending $2.25 billion to buy Precision Medicine Group, a major move in clinical research.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.